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Abstract
Scars are the normal outcome of wound repair and involve a co-ordinated inflammatory and fibrotic process. When a 
scar does not resolve, uncontrolled chronic inflammation can persist and elicits excessive scarring that leads to a range of 
abnormal phenotypes such as hypertrophic and keloid scars. These pathologies result in significant impairment of quality 
of life over a long period of time. Existing treatment options are generally unsatisfactory, and there is mounting interest in 
innovative cell-based therapies. Despite the interest in mesenchymal stem cells (MSCs), there is yet to be a human clinical 
trial that investigates the potential of MSCs in treating abnormal scarring. A synthesis of existing evidence of animal stud-
ies may therefore provide insight into the barriers to human application. The aim of this PRISMA systematic review was 
to evaluate the effectiveness of MSC transplantation in the treatment of hypertrophic and keloid scars in in vivo models. A 
total of 11 case-control studies were identified that treated a total of 156 subjects with MSCs or MSC-conditioned media. 
Ten studies assessed hypertrophic scars, and one looked at keloid scars. All studies evaluated scars in terms of macroscopic 
and histological appearances and most incorporated immunohistochemistry. The included studies all found improvements 
in the above outcomes with MSC or MSC-conditioned media without complications. The studies reviewed support a role 
for MSC therapy in treating scars that needs further exploration. The transferability of these findings to humans is limited 
by factors such as the reliability and validity of the disease model, the need to identify the optimal MSC cell source, and the 
outcome measures employed.
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Introduction
Wounds to the skin are caused by mechanical, thermal, and 
chemical trauma. Scars (or cicatrix) are the normal outcome 
of wound repair and involve a co-ordinated inflammatory and 
fibrotic process. Eventually, the scars remodel and become 
soft, flat, pale, and unobtrusive. When a scar does not resolve, 
persistent chronic inflammation can cause excessive scarring 
that lead to a range of abnormal phenotypes which clinically 
manifest as hypertrophic and keloid scars.
Hypertrophic scars affect nearly one in five people who 
suffer from burns and the risk of scarring increases with 
the time taken to heal (Chipp et al. 2017). They can also 
occur following incisional closure, a standard part of sur-
gical procedures. Typically appearing within 2 months of 
injury, the disease process can be protracted and there-
fore carries significant societal and financial cost over a 
long period of time (Gangemi et al. 2008). Keloid scars 
impact tens of millions of people worldwide, and there 
Christine Bojanic and Kendrick To equally contributed to this 
work.
 * Wasim Khan 
 wasimkhan@doctors.org.uk
1 Plastic & Reconstructive Surgery Department, 
Addenbrooke’s Hospital, Cambridge University Hospitals 
NHS Foundation Trust, Cambridge, UK
2 Division of Trauma and Orthopaedics, Department 
of Surgery, Addenbrooke’s Hospital, University 
of Cambridge, Cambridge, UK
3 School of Clinical Medicine, University of Cambridge, 
Cambridge, UK
4 Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge 
University Hospitals NHS Foundation Trust, Cambridge, UK
5 School of Medicine, Anglia Ruskin University, 
Cambridge & Chelmsford, UK
 Cell and Tissue Research
1 3
is strong evidence of a significant genetic predisposition 
(Bayat et al. 2003; Santos-Cortez et al. 2017). In contrast 
to hypertrophic scars, keloid scars can appear much later 
post-injury and are characterised by extension beyond the 
original area of the trauma. Ultimately, hypertrophic and 
keloid scars result in significant impairment of quality 
of life (Bock et al. 2006). In addition to cosmetic conse-
quences, these abnormal scars can have functional impli-
cations including restricted mobility, pain, and pruritus 
(Bijlard et al. 2017; Lee et al. 2004).
Excess scarring may persist and often recurs after 
multiple interventions (Darzi et al. 1992; Gauglitz et al. 
2011). Most patients suffer from neuropathic pain and 
pruritus, and the mainstay of treatment is conservative 
therapy (Argirova et al. 2006). However, existing treat-
ment options are generally unsatisfactory for patients 
and doctors alike. In particular, surgery, which is mainly 
focused on scar excision, has a very high recurrence rate 
whether used alone or in combination with depot steroids 
(Berman et al. 2009; Furtado et al. 2012; Wilson 2013). 
Strategies aimed at scar growth suppression include 
topical treatments such as retinoic acid, imiquimod, and 
corticosteroid injections (Jacob et al. 2003; Janssen De 
Limpens 1980). These remedies tend to demonstrate 
only short-term efficacy (Berman et  al. 2009; Cação 
et al. 2009). Repeated steroid injections are neverthe-
less efficacious. Pressure therapy and silicone gel cream 
or sheets stand out as clinically useful and widely used 
measures both therapeutically and preventatively (Ai 
et al. 2017; Kim et al. 2014). Modalities such as radio-
therapy, cryotherapy, and lasers have either high failure 
rates, and/ or carry risk of adverse events, not to men-
tion high cost (Manuskiatti and Fitzpatrick 2002; Puri 
and Talwar 2009; Song et al. 2014; Steinstraesser et al. 
2011). Therefore, there is mounting interest in innovative 
methods to treat hypertrophic and keloid scars. Emerg-
ing studies have therefore taken a different approach and 
focussed on cell-based therapies such as mesenchymal 
stem cells (MSCs) (Fung et al. 2017).
MSCs are adult multipotent stromal cells that can be 
readily harvested from various sites such as bone mar-
row, adipose, and umbilical tissue (Baksh et al. 2007; 
Khan et al. 2008). MSCs can be expanded ex vivo and 
cultured under specific conditions to promote particular 
cellular effects. Due to their low immunogenicity, MSCs 
are frequently transplanted allogeneically for the treat-
ment of inflammatory conditions (Kabat et al. 2020). 
MSCs exert their anti-inflammatory and anti-fibrotic 
paracrine effects via the chemokines and microvesi-
cles that they secrete (Badiavas et  al. 2003; Horwitz 
and Dominici 2008; Rani et al. 2015). Excessive scar-
ring involves undesired inflammation that results in 
deposition of immature extracellular matrix (ECM) by 
fibroblasts and myofibroblasts (Barallobre-Barreiro 
et al. 2019). Whilst tissue native MSCs play a key role 
in potentiating this process, there is evidence to sug-
gest that transplanted MSCs are instead able to attenuate 
inflammation and promote a return to homeostasis (Chen 
et al. 2009; Ren et al. 2008). MSCs may achieve this by 
mediating macrophage class switch from a proinflamma-
tory M1 to anti-inflammatory M2 phenotype (Cho et al. 
2014). MSCs also have the potential to negatively modu-
late ECM deposition, possibly via promoting a T-cell 
response that results in the downregulation of TGF-β1, 
a key regulator of collagen synthesis (Huang et al. 2015; 
Spiekman et al. 2014).
Despite the interest in MSCs, there is yet to be a 
human clinical trial that investigates the potential of 
MSCs in treating excessive scarring. A synthesis of 
existing evidence of animal studies will therefore provide 
insight into the barriers to human application. The aim of 
this systematic review was to evaluate the effectiveness 
of MSC transplantation in the treatment of hypertrophic 
and keloid scars in in vivo models.
Materials and methods
A literature search was performed using PubMed, Web of 
Science, and Cochrane Database from conception to May 
2020. The following search terms were used: ((((((((MSC) 
OR Mesenchymal Stem Cell) OR Mesenchymal Stromal 
Cell) OR Multipotent Stem Cell) OR Multipotent Stromal 
Cell) OR Stem Cell)) AND ((Keloid) OR Hypertrophic)) 
AND Scar.
We adhered to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guide-
lines and included case control, cohort studies, case 
series, and randomised controlled trials (Moher et al. 
2009). A total of 1098 studies were subjected to the 
inclusion/exclusion criteria, yielding a final 11 studies 
for qualitative analysis (Fig. 1). Studies that evaluated 
MSC or MSC-conditioned media transplantation as ther-
apies were included. Studies that assessed in vivo mod-
els were included. Studies of all design were included. 
Literature reviews, systematic reviews, and case reports 
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were excluded but were reverse-reference searched to 
maximise yield. Studies with only in vitro experiments 
were excluded. All included studies were published in the 
English language, and all unpublished, inaccessible, and 
retracted literature were excluded. CB and KT carried out 
the search independently. Risk of bias was assessed by 
Fig. 1   Flow diagram of search 
strategy
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AH and JS using the SYRCLE RoB tool (Table 1; Fig. 2) 
(Hooijmans et al. 2014).
Results
A total of 11 studies were identified (Tables 2, 3, and 
4) (Domergue et al. 2016; Foubert et al. 2017; Hu et al. 
2019, 2020; Li et al. 2016; Liu et al. 2018, 2014; Yates 
et  al. 2017; Yates et  al. 2017; Zhang et  al. 2015). A 
total of 156 subjects were treated with MSCs or MSC- 
conditioned media. There were no significant complica-
tions reported in any of the studies. Ten studies assessed 
the effectiveness of MSCs or MSC-conditioned media in 
treating hypertrophic scars and one in keloid scars. All 
studies were case control studies.
MSC isolation and characterisation
Six studies used bone marrow MSCs: two of murine ori-
gin (Hu et al. 2019, 2020), two of human origin (Yates 
et al. 2017; Yates et al. 2017), one of rabbit origin (Liu 
et al. 2014), and one study included both human and 
rabbit origin MSCs (Liu et al. 2014). Five of the studies 
that employed bone marrow MSCs harvested cells by 
needle aspiration from either the tibia, femur or poste-
rior iliac crest (Hu et al. 2019, 2020; Liu et al. 2014; Liu 
et al. 2014; Yates et al. 2017). One study, by Yates et al. 
(Yates et al. 2017) used bone marrow MSCs derived from 
an immortalised cell line. Five studies utilised adipose 
MSCs: three of human (Domergue et al. 2016; Li et al. 
2016; Liu et al. 2018), one of porcine (Foubert et al. 
2017) and one of rabbit origin (Zhang et al. 2015). Three 
studies experimented MSCs from inguinal fat pad or 
redundant tissue from surgical operations (Foubert et al. 
2017; Liu et al. 2018; Zhang et al. 2015). Domergue et al. 
(2016) extracted MSCs by dermolipectomy and Li et al. 
(2016) by liposuction. Whilst all the studies applied flow 
cytometry to characterise MSCs, only four satisfied the 
International Society for Cellular Therapy (ISCT) crite-
ria for defining MSCs by also performing tri-lineage dif-
ferentiation (Dominici et al. 2006; Hu et al. 2019, 2020; 
Yates et al. 2017; Yates et al. 2017). Five studies per-
formed bi-lineage differentiation only (Li et al. 2016; Liu 
et al. 2018, 2014; Liu S. et al. 2014; Zhang et al. 2015).
MSC treatment and delivery
Most studies passaged MSCs at least three times. Only 
two studies used MSCs from earlier passage; Domergue 
et al. (2016) used passage one, and Foubert et al. (2017) Ta
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did not passage the cells at all. Interestingly, two studies 
harvested MSCs beyond the eighth passage (Hu et al. 
2019, 2020). Studies transplanted varying concentrations 
of MSCs but at similar volumes of around 200 μl. Two 
studies administered 1000 μl (Li et al. 2016; Liu et al. 
2014), whilst three studies dispensed less than 100 μl 
of MSCs (Domergue et al. 2016; Liu. et al. 2018; Yates 
et al. 2017). Yates et al. (Yates et al. 2017) did not spec-
ify the quantity given. The routes of MSC administration 
were highly variable. Eight of the eleven studies deliv-
ered MSCs or MSC-conditioned media by subcutane-
ous injection. Of these, four studies specified further; 
two injected four points of the wound (Domergue et al. 
2016; Liu et al. 2018), one injected into the centre of 
each wound (Zhang et al. 2015), and the fourth deliv-
ered MSCs by circumferential intradermal injection into 
each wound (Liu et al. 2014). Of the remaining three 
studies, one study delivered MSCs onto the wound via 
an aerosol (Foubert et al. 2017), one applied the MSCs 
to fill the wound defect (Yates et  al. 2017), and one 
injected MSCs intra-arterially (Liu et al. 2014). Five 
of the eleven studies utilised MSC-conditioned media 
(Hu et al. 2019, 2020; Li et al. 2016; Liu et al. 2018; 
Zhang et al. 2015). Two studies used chemokine recep-
tor 3 (CXCR3) knockout mice, which are known to scar 
excessively when wounded (Yates et  al. 2017; Yates 
et al. 2017). Four studies employed internal controls by 
injecting MSCs on the contralateral side of the animal 
subject (Foubert et al. 2017; Hu et al. 2019; Yates et al. 
2017; Zhang et al. 2015). Five studies utilised Dulbecco’s 
modified Eagle media (DMEM) (Hu et al. 2019, 2020; 
Li et al. 2016; Liu et al. 2018; Zhang et al. 2015), and 
three applied phosphate buffer solution (PBS) as controls 
(Domergue et al. 2016; Liu et al. 2014; Liu et al. 2014). 
Other control groups comprised lactated Ringer’s solu-
tion (LR), hyaluronic acid (HA), and no treatment as 
a control (Foubert et al. 2017; Yates et al. 2017; Yates 
et al. 2017). The majority of studies followed up wound 
progression for at least 28 days.
Disease model
Eight studies evaluated the effectiveness of MSCs in 
preventing hypertrophic scar formation (Table 3), and 
three studies examined MSC therapy on formed scars. In 
Fig. 2   Overall risk of bias
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the latter, one study assessed keloid scars and included 
four subjects. Six studies assessed murine, four used rab-
bit, and one utilised a porcine subject. All the induced 
wounds were full dermal-thickness but varied in size and 
location, with the majority being circular punch wounds 
inflicted on the dorsum of murine subjects. Four studies 
Table 2  MSC isolation and characterisation
Author MSC source Method of tissue extraction MSC characterisation MSC treatment
Hu et al. (2019) Murine bone marrow Needle aspiration from tibia 
and femur
Flow cytometry (CD150+/
CD74+), tri-lineage dif-
ferentiation (osteogenic, 
adipogenic, chondrogenic)
Passages 8–13 harvested at 
70%
Hu et al. (2019) Murine bone marrow Needle aspiration from tibia 
and femur
Flow cytometry (CD105 + /
CD73+), tri-lineage dif-
ferentiation (osteogenic, 
adipogenic, hepatogenic)
Passages 8–13 harvested at 
70%
Liu et al. (2018) Human adipose Surgical excision of redun-
dant tissue from surgical 
operations
Flow cytometry (CD105+/
CD90+/CD34-/CD45-/
CD19-), adipogenic and 
osteogenic differentiation
Passages 3–4
Foubert et al. (2017) Porcine adipose Surgical excision of inguinal 
fat pad
Flow cytometry (CD90+/
CD45-)
Untreated, re-suspended in 
buffer solution and delivered 
two hours following isolation
Yates et al. (2017) Human bone marrow Immortalised cell line Flow cytometry (CD105+/
CD14-/CD34-/CD45-), 
tri-lineage differentiation 
(osteogenic, adipogenic, 
chondrogenic)
Passage 4 harvested at 70%
Yates et al. (2017) Human bone marrow Needle aspiration from poste-
rior iliac crest
Flow cytometry (CD105+/
CD14-/CD34-/CD45-), 
tri-lineage differentiation 
(osteogenic, adipogenic, 
chondrogenic)
Passage 3 harvested at 70%
Domergue et al. (2016) Human adipose Dermolipectomy Flow cytometry (CD73+/
CD90+/CD34-/CD14-)
End of passage 1
Li et al. (2016) Human adipose Liposuction Flow cytometry (CD73+/
CD90+/CD34-/CD14-), 
adipogenic and osteogenic 
differentiation
Passages 3–5 starved for 24 h 
at 80–90% confluence prior 
to supernatant collection
Zhang et al. (2015) Rabbit adipose Surgical excision of inguinal 
fat pad
Flow cytometry (CD73+/
CD90+/CD34-/CD14-), 
adipogenic and osteogenic 
differentiation
Passage 3 harvested at 80–90%
Liu et al. (2014) Human bone marrow 
and rabbit bone 
marrow
Human: bone marrow biopsy 
Rabbit: bone marrow needle 
aspiration
Flow cytometry (CD105+/
CD90+/CD34-/CD45-), 
chondrogenic and osteo-
genic differentiation
Passage 3–4
Liu et al. (2014) Rabbit bone marrow Needle aspiration from tibia 
and femur
Flow cytometry (CD105 + /
CD90 + /CD34-/CD45-), 
adipogenic and osteogenic 
differentiation
Passage 4–6
Cell and Tissue Research 
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inflicted full-thickness punch wounds on the ears of rab-
bit subjects (Hu et al. 2019; Liu et al. 2014; Liu et al. 
2014; Zhang et al. 2015). Three studies (Table 4) created 
full-thickness skin wounds on human skin samples which 
were then xenografted onto murine subjects (Domergue 
et al. 2016; Hu et al. 2020; Liu et al. 2018).
Treatment outcomes and complications
All studies assessed wounds in terms of macroscopic 
appearance and histology with most including immuno-
histochemistry. No complications were reported by any of 
the studies. Gross appearance was evaluated in all studies 
using high-resolution photography, and all studies reported 
positive improvements in various measured parame-
ters in the MSC-treated group compared with controls. 
Eight studies described reduced scar hypertrophy in the 
MSC-treated group compared with controls (Domergue 
et al. 2016; Foubert et al. 2017; Hu et al. 2019, 2020; Li 
et al. 2016; Yates et al. 2017; Yates et al. 2017; Zhang 
et al. 2015). Two studies reported that MSC-treated sub-
jects attenuated hypertrophic scar formation (Liu et al. 
2014; Liu et al. 2014). One study evaluated keloid size 
and found greater scar shrinkage following treatment (Liu 
et al. 2018). Several studies assessed collagen character-
istics using assays of collagen gel contraction (Hu et al. 
2019), collagen deposition (Foubert et al. 2017; Hu et al. 
2020), and collagen content (Domergue et al. 2016). All 
studies reported reduced collagen deposition and reduced 
collagen contracture in the MSC-treated group compared 
with controls. Two studies assessed fibroblast apoptosis. 
Hu et al. (2020) found increased fibroblast apoptosis by 
staining for caspase-7. Liu et al. (2018) measured the pres-
ence of phosphatidylserine in the outer layer of the phos-
pholipid bilayer as a surrogate marker of apoptosis and 
found no change in the MSC-treated group compared with 
control. Another study used TUNEL (terminal deoxynu-
cleotidyl transferase dUTP nick end labelling) staining to 
assess MSC apoptosis and found that a significant propor-
tion of MSCs underwent apoptosis after administration 
onto a wound (Liu et al. 2014). Three of the eleven studies 
assessed scar thickness, with two using digital planim-
etry (Foubert et al. 2017; Liu et al. 2014) and one using 
ultrasonography (Zhang et al. 2015). All studies reported 
reduced scar tissue height and hardness. Yates et  al. 
(2017), by staining caspase-3 with a fluorescent probe, 
found reduced caspase-3, suggesting improved fibroblast 
survival following MSC co-transplantation.
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Discussion
Although the outcomes reported in this review generally 
favour MSC transplantation in treating excessive scarring 
and did not report complications, it is difficult to draw reli-
able conclusions due to the heterogeneity of the studies. This 
arises from various aspects; there was significant variability 
in the cell source, cell treatment, method of delivery, and the 
disease model used to assess efficacy. Most studies demon-
strated moderate to high overall risk of bias as they were 
aiming to different and more specific questions relevant to 
MSC use. Nevertheless, this systematic review provides a 
useful summary and helps inform future study design.
The properties of MSCs can vary according to the cell 
source. Consistent with the existing literature, most of our 
studies examined adipose MSCs (AMSCs) and bone mar-
row MSCs (BMMSCs) (Kabat et al. 2020). Both of these 
cell sources have their relative advantages for use in treat-
ing scars. AMSCs offer a greater capacity to proliferate 
ex vivo compared with other cell sources (Peng et al. 2008) 
and therefore may be suitable for large scale off-the-shelf 
preparations at greater cost-effectiveness. They may also 
be more abundant, less invasive to harvest, and are often 
available as medical waste in many cosmetic surgery pro-
cedures. BMMSCs may represent a less heterogenous cell 
population (Liu et al. 2013) but exhibit senescence at earlier 
passage (Burrow et al. 2017). An important consideration is 
that the anti-inflammatory properties of MSCs could differ 
by cell source. Particular studies suggest that AMSCs may 
be superior in promoting an M1 to M2 phenotype transi-
tion in macrophages that favour resolution of inflammation 
(Heo et al. 2019). This is relevant as macrophages are a key 
mediator of the pathogenic process of excessive scarring 
(Feng et al. 2019; Hesketh et al. 2017). In addition, certain 
MSCs demonstrate a greater ability to engraft onto lesions 
and can therefore produce more sustained effects (Burk et al. 
2016). One study in this review compared human and rab-
bit cell sources and found both cell sources to be equally 
efficacious (Liu et al. 2014). Harvesting MSCs from ani-
mals rather than humans may be more convenient but the 
immunogenic consequences of xenogeneic transplantation 
with human recipients are yet to be thoroughly investigated. 
Although heterogeneity of MSC origin and culture condi-
tion among the included studies may affect the reliability 
of conclusions drawn from them, it is reassuring that posi-
tive effects were observed across multiple cell sources. This 
indicates that MSCs regardless of origin have the potential 
to treat hypertrophic and keloid scars. Future studies should 
aim to identify the best cell source for treating excessive 
scarring.
Significant heterogeneity was also observed between the 
studies in terms of culture conditions and treatment delivery 
methods. The literature suggests that pre-conditioning MSCs 
with inflammatory cytokines may serve to promote an 
anti-inflammatory MSC phenotype (Saldaña et al. 2019). 
Similarly, following co-culture with fibroblasts, a cell type 
prevalent in inflamed scars, MSCs express greater levels of 
anti-inflammatory cytokines (Suzuki et al. 2017). This sug-
gests that treating MSCs in conditions reflective of the scar 
environment might potentiate their effectiveness when used 
in transplantation. Conversely, serum-free culture conditions 
appear to enhance the anti-fibrotic properties of MSCs in vivo 
(Yoshida et al. 2018). This may represent a potential challenge 
as the optimal culture protocol should promote an anti-fibrotic 
response without compromising the anti-inflammatory prop-
erties of MSCs. One way of circumventing this could be to 
stimulate MSCs under a particular set of culture conditions, 
and then harvesting the conditioned media that contains bio-
active extracellular vesicles (EVs). The MSCs can then be 
resuspended and grown under a different set of culture condi-
tions to promote secretion of different bioactive substances. 
Indeed, several studies in our review showed that a cell-free 
treatment using MSC-conditioned media can be effective (Hu 
et al. 2019, 2020; Li et al. 2016; Zhang et al. 2015).
On the other hand, it is difficult to identify the best 
MSC delivery method. MSCs injected into the circu-
lation appear to engraft well into wounds (Deng et al. 
2005), but carry a risk of interacting with cytokines and 
drugs present in the serum, which may alter MSC func-
tion (Javorkova et al. 2018). In contrast, MSCs injected 
directly into a lesion of interest could delocalise rapidly 
(Burk et al. 2016) and therefore still have the potential 
to exert off-site effects (Devine et al. 2003). Although 
there were no complications reported in any of the stud-
ies in this review, several factors have the potential to 
influence MSC biodistribution and therefore clinical 
efficacy following administration. It has been reported 
that pulmonary complications relating to IV administra-
tion of MSCs could be dependent on the cell suspension 
formulation (Deak et al. 2010). Other studies suggest 
that following initial localisation in the lungs follow-
ing systemic administration, MSCs can home to areas 
of inflammation (Rustad and Gurtner 2012). Although 
useful in cases of isolated skin pathology, undesired 
offsite effects may be observed in cases of other under-
lying systemic inflammation (Gholamrezanezhad et al. 
2011). There is also evidence to show that the migration 
and proliferation of MSCs at skin wounds can be a func-
tion of MSC expression of adhesion molecules includ-
ing junction adhesion molecule A (JAM-A) (Wu et al. 
2015). Likewise, chemokines such as CCR7 also appear 
to promote MSC migration to skin wounds (Sasaki et al. 
2008). For the purposes of treating scars, it appears 
that local administration may be preferable, with recent 
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studies demonstrating safety in animals via subcutaneous 
(Tappenbeck et al. 2019) and topical (Beyazyildiz et al. 
2014) routes. Robust experiments that compare methods 
of MSC delivery in treating scars should address this 
ambiguity.
It remains uncertain whether interpretations drawn from 
animal models of excessive scarring can be transferred 
directly to inform treatment in humans. Most of the studies 
in this review assessed the effects of MSCs on the degree 
of hypertrophy during the scarring process. This prob-
ably does not replicate the human disease where patients 
typically present with a fully formed scar. Nevertheless, 
it may inform whether MSCs can be implemented at the 
time of injury (in high risk patients) or shortly after or 
in conjunction with surgical scar treatment as a means 
of preventing primary or recurrent hypertrophic or keloid 
scars. Genetic models of hypertrophic scarring may confer 
high reproducibility. There are existing gain-of-function 
models such as the Tight Skin 2 mouse which exhibit 
increased fibrosis following injury (Long et al. 2014), pre-
sumably due to increased collagen III alpha-1 expression 
(Long et al. 2015). Instead of a gain-of-function model, 
the two studies by Yates et al. (Yates et al. 2017; Yates 
et al. 2017) captured in this review utilised a previously 
validated knockdown model by targeting the CXCR3 gene 
(Yates et al. 2010). Whilst both methods may be informa-
tive for in vivo studies of hypertrophic scarring, they do 
not reflect the pattern of genetic predisposition in humans 
(Zhu et al. 2013), and the knock-down target does not cor-
relate with known protective genetic variants (Sood et al. 
2015). It is suggested that concomitantly xenografting 
human skin cells into the wound may improve the validity 
of the mouse burns model by promoting a more extensive 
scar phenotype (Ibrahim et al. 2014; Momtazi et al. 2013). 
However, this could be confounded by the immunogenic 
effects of xenografting skin onto an immunocompetent 
mouse (Racki et al. 2010). Nevertheless, the studies in 
this review that conducted xenografting of human skin into 
mouse defects did not observe graft rejection (Domergue 
et al. 2016; Hu et al. 2019; Liu et al. 2018).
Another issue relates to the time-course of scar patho-
genesis. Most mouse models develop mature hypertrophic 
or keloid scarring within days to weeks after burn injury 
and weeks to months after incisional injury (Kim et al. 
2018), unlike the longer time course of human disease. 
In humans, excessive scarring can occur after months 
(Gangemi et al. 2008), with biomolecular evidence of 
active disease at up to a year later (Van Der Veer et al. 
2011). There is evidence in the literature to support the 
potential use of the Red Duroc porcine model, which 
develops scarring over months instead, and therefore bet-
ter recapitulates the human process (Harunari et al. 2006; 
Zhu et al. 2003, 2004). We captured one study by Foubert 
et al. (2017) that was able to utilise this model in order 
to undertake an extended follow-up period of six months, 
when active scar growth was still observed. Whilst all of 
the studies demonstrated sustained benefit and did not 
report recurrence up to the end point of follow-up, keloid 
and hypertrophic scars are known in humans to recur 
after many months to years following successful treat-
ment (Furtado et al. 2012). Therefore, the short lifespan 
of murine models may not permit sufficient longitude to 
assess whether the benefits of MSC therapy is sustained. 
Future studies of porcine models with long follow-up 
periods may facilitate this.
In order to fully exploit the beneficial effects of MSCs 
in treating scars, it is important to establish a dose-response 
relationship. The studies in this review varied significantly 
in the amount of MSC or MSC-conditioned media used, but 
all reported positive outcomes. Only one study examined the 
effects of varying the dose of MSC-conditioned media used and 
found a dose-response relationship (Li et al. 2016). It is unclear 
whether the same relationship may be observed in treatment 
with MSCs of varying concentration and there is evidence in 
models of ischaemic injury that higher doses of MSCs do not 
always confer greater therapeutic benefit (Yavagal et al. 2014). 
Therefore, a relevant future study might aim to determine the 
maximum tolerated dose (MTD) for MSCs in treating keloid 
and hypertrophic scars. The method of delivery might influence 
this, as appropriate dosage for intravenous injection may be 
derived from the weight of the subject, whereas intralesional 
delivery may require the volume of the scar of interest to be cal-
culated. Digital planimetry, as employed by several studies here, 
may be a viable method of achieving this (Foubert et al. 2017; 
Liu et al. 2014). Ascertaining the MTD will also inform safe 
dosages that do not evoke adverse effects (Karussis et al. 2010). 
Six studies in this review treated scars with MSCs, four studies 
used conditioned media, and one compared the two. There has 
been an emerging body of evidence to support the use of con-
ditioned media, which contains bioactive extracellular vesicles 
(EVs) that may be the active therapeutic ingredient of MSCs 
(Furuta et al. 2016). As a cell-free therapy, it is possible that 
EVs are less immunogenic and may therefore be more suitable 
for large-scale production from allogeneic sources (Monguió-
Tortajada et al. 2017).
Outcome measures utilised by in vivo studies can limit 
their transferability to humans. Whilst reduction in scar size 
and improvement in histological appearance may reflect the 
cosmetic benefits of treatment, it is unclear how it affects 
scar symptoms. As pain and pruritis are the main symptoms 
of hypertrophic and keloid scars (Lee et al. 2004), func-
tional assessments in animals may be crucial before under-
taking human trials. For example, there are well-validated 
and quantifiable behavioural measures such as vocalisation 
that reflect pain in mice (Kurejova et al. 2010). Assessing 
the degree of physical activity such as time spent digging 
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(Shepherd et al. 2018) could potentially reveal the functional 
implications of contractures resulting from scars, although 
this could be dependent on the position of the lesion. Aside 
from looking to reduce the amount of scarring, there is a 
range of symptoms that can be caused by excessive scar-
ring, and so separate studies may be required to evaluate 
the differential benefits of MSC therapy and to determine a 
personalised approach according to the specific symptom.
Conclusion
The present review suggests that mesenchymal stem cell 
(MSC) therapy can be an effective method of treating hyper-
trophic and keloid scars across a range of cell sources and 
animal models and does not cause significant complications. 
However, there is inadequate high-level evidence of in-
human studies to support clinical efficacy in humans. There 
are several areas that need to be addressed before proceeding 
to human trials. This includes the identification of a reli-
able, reproducible, and validated animal model, and a stand-
ardised method of MSC delivery to allow a dose-response 
relationship to be established. The similar positive results 
observed to date with MSCs and MSC-conditioned media 
are encouraging and should be explored further by assessing 
the efficacy of MSC-derived extracellular vesicles, as this 
will carry significant implications for cost-effectiveness in 
treating humans at a population scale.
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